HHS Issues Interim Policy on Compounding Six Peptides, Including BPC-157 and TB-500

What happened / Why it matters

What happened. On Oct. 30, 2026, the Department of Health and Human Services (HHS) published an interim enforcement policy for six peptides: BPC-157, TB-500, epitalon, semax, KPV and MOTS-c. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds a drug from one of these substances, as long as ten conditions are all met. The notice calls the document a draft and opens public comment.

Why it matters. The policy changes how federal regulators say they will treat certain compounding. It does not change what is known about whether these peptides work or how safe they are. None of the six is FDA-approved, and the policy says in its own text that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.

What does the policy actually say?

The Federal Register notice announces the availability of the policy while the list of bulk drug substances allowed under section 503A of the Federal Food, Drug, and Cosmetic Act “is developed through rulemaking.” Until a final rule addresses each peptide, the HHS policy says HHS “does not intend to take enforcement action” when all of its conditions are present.

The policy is narrow about what is covered. Appendix B names a specific form of each substance and the routes of administration it covers:

The ten conditions include, in summary:

• The substance matches the identity and route described in Appendix B.
• It comes with a certificate of analysis, and the original manufacturer is registered with FDA and in compliance with current good manufacturing practice.
• The compounder reports products, serious adverse events and product quality problems to FDA’s MedWatch program and to the relevant states.
• The label reads “This is a compounded drug product. Not for resale.”
• The product contains only one active ingredient from the list.
• Oral products need documentation that the specific formulation reaches adequate oral bioavailability in humans.
• The only co-packaged delivery device is an FDA 510(k)-cleared syringe.
• The drug is made on a patient-specific prescription and otherwise complies with the law, including rules against insanitary conditions.

HHS’s stated aim is to steer patients away from “research-use-only peptides supplied by foreign manufacturers” toward “a more controlled alternative.” Whether it achieves that is not something the document can show.

What does the policy not say?

• It is not FDA approval. The text states that compounded drugs are not FDA-approved.
• It does not add these peptides to the 503A list. HHS says future FDA rulemaking “may propose adding some or all of these peptides” to that list based on the available evidence. Until then, the policy is a statement about enforcement.
• It creates no rights and can change. The notice says the policy “does not establish any rights for any person and is not binding on HHS or the public,” and that HHS may revisit it if, for example, a safety signal or a product quality problem appears.
• It is open for comment. Written comments are accepted for two weeks after publication on regulations.gov, which lists the deadline as 11:59 p.m. Eastern on Nov. 13. The notice itself calls the document a draft in one place and a policy in another, so we describe it as an interim policy open for public comment.
• It names pharmacies, federal facilities and physicians. Outsourcing facilities (the 503B category) are not named in the operative text. A law-firm analysis (secondary source) reads the policy as not covering 503B or blends such as BPC-157 plus TB-500; the single-ingredient condition is in HHS’s own text.
• It does not replace state law. Per the same analysis, state pharmacy rules are separate from HHS’s federal enforcement stance. Before the policy was issued, boards in Alabama and Mississippi told licensees they may not compound, administer or dispense non-FDA-approved or research-grade peptides. We found no update from them as of Oct. 31, and it isn’t clear how those notices apply to compounding under the HHS policy.

How did we get here?

HHS’s appendix justifies each peptide with updated lot-level test results, historical use it calls “documented and quantified,” and either the policy’s conditions or its own reading of the safety record. For BPC-157, it says the certificate was “not before CDER.” The policy document does not reproduce those certificates or the use data. It also cites “multiple human studies” for BPC-157 without naming them. CDER and HHS reach different conclusions, and the document does not publish the material that would let readers weigh the two. The public comment period is where that can be tested.

A law-firm analysis (secondary source) estimates a final rule could take 12 to 24 months.

What do we know about the evidence for these peptides?

The policy is not an evidence review, and the evidence differs by peptide. This report covers two of the six:

• BPC-157: FDA evaluated it for ulcerative colitis and found a “lack of evidence” to support its effectiveness. It says human studies were short and small.
• TB-500: FDA says TB-500 and thymosin beta-4 are not the same substance. It identified no clinical studies or human exposure data for TB-500 by any route, and says its potential risks in humans are unknown. HHS points to the human safety record of the parent protein.

We have not reviewed the evidence for epitalon, semax, KPV or MOTS-c for this article and make no claim about it. The policy’s own text describes the CDER safety concerns for some of them as “mechanistic” or “an absence of information” rather than observed harm, which is HHS’s characterization.

What does this mean for a reader?

• Federal non-enforcement is not a statement that a product works or is safe.
• If a clinician offers one, ask which form and route is being used, whether the pharmacy can show the certificate of analysis, and what the evidence is for the specific condition.
• Products sold online as “research use only” are not compounded drugs made on a prescription. HHS describes them as a safety risk in the policy itself. We do not link to or recommend sellers.
• Anyone who has a serious reaction can report it to FDA’s MedWatch program, the same channel the policy requires compounders to use.
• No dosing, cycle or preparation guidance appears here, and none should be taken from a news article.

Regulatory status verified Oct. 31, 2026. This situation is moving: the policy is open for comment and HHS can revise it. We will update this article with a visible note when it changes.